The ASPRE trial (2017) validated the use of first-trimester combined screening (maternal factors + uterine artery Doppler + PlGF + MAP) to predict pre-eclampsia and evaluated aspirin prophylaxis. The trial found that aspirin 150 mg daily given to high-risk women from 11–14 weeks onwards reduced the rate of preterm pre-eclampsia by approximately:

• A 15% relative risk reduction
• B 25% relative risk reduction
• C 82% relative risk reduction
• D 62% relative risk reduction ✓

Explanation

The ASPRE (Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Pre-eclampsia Prevention) trial demonstrated that aspirin 150 mg daily from 11–14 weeks in women identified as high-risk by first-trimester combined screening reduced the rate of preterm pre-eclampsia (< 37 weeks) by approximately 62% (from 1.6% to 0.38%). There was no significant reduction in term pre-eclampsia. This established first-trimester screening plus aspirin prophylaxis as the standard approach in high-risk women.

Reference: Williams Obstetrics, 26th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.